Company Overview

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Founded in 2003, the company is headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK. Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024 following significant breakthroughs in its lead drug candidate, ivonescimab.

Lead Product: Ivonescimab

Ivonescimab is the company's lead development candidate, a bispecific antibody designed for immunotherapy. It works by blocking PD-1 and providing anti-angiogenesis effects. It is currently in Phase III clinical trials for the treatment of non-small cell lung cancer (NSCLC). Ivonescimab, known as SMT112 in Summit's license territories (North America, South America, Europe, the Middle East, Africa, and Japan), and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody. It combines the effects of immunotherapy via PD-1 blockade with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.

FDA Fast Track Designation

The U.S. Food and Drug Administration ("FDA") has granted Fast Track designation for the proposed use of ivonescimab in combination with platinum-based chemotherapy. This designation is for adult patients with locally advanced or metastatic NSCLC with EGFR mutation, who have experienced disease progression following EGFR-TKI therapy.

Clinical Trial Program

Summit is conducting multiple Phase III clinical trials for ivonescimab:

HARMONi Trial

In October 2024, enrollment was completed for the HARMONi clinical trial. Topline results are expected in mid-2025, depending on data maturation. Summit Therapeutics previously announced positive topline results from HARMONi, a global Phase III trial evaluating ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients. The study met its primary endpoint, showing a 48% reduction in disease progression or death risk compared to chemotherapy alone (HR=0.52, p<0.00001).

HARMONi-3 Trial

In the fourth quarter of 2024, the HARMONi-3 protocol was amended to include patients with both squamous and non-squamous histologies. This change significantly increases the eligible patient population for the proposed indication.

HARMONi-7 Trial

Summit has announced its intention to launch a third Phase III clinical trial, HARMONi-7, expected to initiate in early 2025. This trial will investigate ivonescimab monotherapy in first-line metastatic NSCLC patients whose tumors have high PD-L1 expression without actionable genomic alterations. The study is planned for an estimated 780 patients with two primary endpoints: PFS and OS.

Strategic Partnerships

Akeso Collaboration

In January 2023, Summit closed its Collaboration and License Agreement with Akeso Inc. Summit's partner, Akeso, has achieved significant milestones. On April 23, 2025, Akeso announced that the HARMONi-6 Phase III clinical trial met its primary endpoint of progression-free survival (PFS) at a prespecified interim analysis conducted by an Independent Data Monitoring Committee.

Pfizer Collaboration

A Clinical Trial Collaboration with Pfizer is underway, evaluating Ivonescimab in combination with several Vedotin ADCs in unique solid tumor settings. Clinical trials are expected to commence by mid-2025.

Financial Position

Summit has maintained a strong financial position to support its clinical development programs:

Cash Position

- Aggregate cash and cash equivalents, and short-term investments were approximately $487 million as of September 30, 2024.

- Financially, Summit reported cash and investments of $361.3 million as of March 31, 2025.

- Aggregate cash and cash equivalents and short-term investments were $297.9 million and $412.3 million at June 30, 2025 and December 31, 2024, respectively.

Recent Financings

"With the recent financing in September 2024 providing us $235 million, we have strengthened our cash balance to extend our cash runway," said Manmeet S. Soni, Summit's Chief Operating Officer and Chief Financial Officer. In September 2024, the company closed a private financing of $235 million with multiple leading biotech institutional investors and insiders.

Q1 2025 Financial Results

- GAAP net loss in the first quarter of 2025 was $62.9 million or $(0.09) per basic and diluted share, compared to $43.5 million or $(0.06) per basic and diluted share in Q1 2024.

- Non-GAAP operating expenses were $55.7 million for the first quarter of 2025, compared to $32.9 million for the same period of the prior year. The increase is primarily related to higher R&D expenses due to the expansion of clinical studies and development costs for ivonescimab, along with increased people costs.

Regulatory Status

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. However, ivonescimab was initially approved for marketing authorization in China in May 2024, and its label was expanded in China in April 2025.

Analyst Coverage

According to 18 analysts, the average rating for SMMT stock is "Strong Buy." The 12-month stock price target is $34.12, which represents an increase of 80.63% from the latest price.

Summit Therapeutics represents a compelling opportunity in the oncology space with its innovative bispecific antibody approach to treating lung cancer. The company's robust clinical program, strong financial position, and strategic partnerships position it well for continued advancement in bringing potentially transformative cancer treatments to patients.